Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.8569 USD
−6.98 M USD
75.72 K USD
2.94 M
About Arch Therapeutics, Inc.
Sector
Industry
CEO
Terrence W. Norchi
Website
Headquarters
Framingham
Founded
2009
FIGI
BBG002PHNCD4
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ARTH is 0.2300 USD — it hasn't changed in the past 24 hours. Watch Arch Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Arch Therapeutics, Inc. stocks are traded under the ticker ARTH.
ARTH stock has risen by 21.05% compared to the previous week, the month change is a −0.20% fall, over the last year Arch Therapeutics, Inc. has showed a −95.31% decrease.
ARTH reached its all-time high on Jul 11, 2013 with the price of 272.0000 USD, and its all-time low was 0.1700 USD and was reached on Dec 9, 2024. View more price dynamics on ARTH chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ARTH stock is 33.95% volatile and has beta coefficient of 2.63. Track Arch Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Arch Therapeutics, Inc. there?
Today Arch Therapeutics, Inc. has the market capitalization of 1.02 M, it has increased by 3.76% over the last week.
Yes, you can track Arch Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Arch Therapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ARTH net income for the last quarter is −5.65 M USD, while the quarter before that showed −1.47 M USD of net income which accounts for −284.90% change. Track more Arch Therapeutics, Inc. financial stats to get the full picture.
No, ARTH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 8.00 employees. See our rating of the largest employees — is Arch Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arch Therapeutics, Inc. EBITDA is −4.72 M USD, and current EBITDA margin is −6.66 K%. See more stats in Arch Therapeutics, Inc. financial statements.
Like other stocks, ARTH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arch Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arch Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arch Therapeutics, Inc. stock shows the sell signal. See more of Arch Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.